|Table of Contents|

Effect of different dose fractionated radiotherapy on serum EGFR and TGF-α in patients with locally advanced non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 02
Page:
229-232
Research Field:
Publishing date:

Info

Title:
Effect of different dose fractionated radiotherapy on serum EGFR and TGF-α in patients with locally advanced non-small cell lung cancer
Author(s):
Ge Qin1; Qian Xia1; Wu Jianting1; Xie Guodong1; Cai Jing1; Yang Baixia1; Zhao Jizhong1; Yin Haibing2; Chu Chunxia1
1.Department of Radiotherapy;2.Department of Pathology,Nantong Tumor Hospital，Jiangsu Nantong 226361，China.
Keywords:
locally advanced non-small cell lung cancer; large dose fraction radiotherapy; epidermal growth factor receptor; transforming growth factor-α
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2019.02.012
Abstract:
Objective:To observe the therapeutic effect of large dose fraction radiotherapy on locally advanced non-small cell lung cancer (NSCLC),and to explore the changes of serum levels of EGFR and TGF-α before and after radiotherapy and its clinical significance.Methods:Seventy patients with locally advanced NSCLC were selected in the Department of Radiotherapy in the hospital from July 2011 to July 2016.They were divided into conventional fraction radiotherapy group (prescription dose PTV 60 Gy/30 f,a single dose 2 Gy) and large dose fraction radiotherapy group (prescription dose of PTV 50 Gy /10 f,a single dose of 5 Gy).The efficacy was observed in two groups after the treatment,and the expression levels of epidermal growth factor receptor (EGFR) and transforming growth factor-α (TGF-α) of patients were analysed by radioimmunoassay and enzyme-linked assay.Results:The effective rate and stability rate of thoracic lesions in large dose fraction radiotherapy group were 75.00% and 85.00%,respectively,which were significantly higher than those in conventional fraction radiotherapy group (68.00% and 80.00%,P＜0.05).Hypo-fractionated radiotherapy group and conventional radiotherapy group before treatment of serum EGFR,TGF-α content was respectively (24.31±4.06) μg/L,(26.30±2.16) μg/L and (24.42±4.04) μg/L,(25.96±2.24) μg/L,the two groups had no significant difference (P＞0.05),two groups after treatment of serum EGFR,TGF-α content was respectively (12.11±3.58) μg/L,(14.13±1.72) μg/L and (14.31±3.64) μg/L,(18.25±1.65) μg/L,there were statistically significant difference (P＜0.05).Conclusion:In the large dose fraction radiotherapy group,there was a higher control rate than the conventional radiotherapy group without increasing the side effects,which might be associated with the down regulation of EGFR and TGF-α levels in patients' serum.Therefore,large-segment radiotherapy is expected to be a new choice for radiation dose partitioning in patients with locally advanced NSCLC.

References:

［1］Li Xiangju.Pathological interpretation:lung cancer-small world big universe series (fourteen)［J］.Cancer Rehabilitation,2014,9(4):24-27.［李香菊.病理解读：肺癌-小世界大乾坤系列之（十四）［J］.癌症康复,2014,9(4):24-27.］
［2］Xiao J,Xu X,Li X,et al.Re-188 enhances the inhibitory effect of Bevacizumab in non-small-cell lung cancer［J］.Molecules,2016,21(10):1308.
［3］Yuan Baolin,Zhang Tao,Luo Jianqi，et al.Three dimensional conformal radiotherapy (3DCRT) non-small cell lung cancer clinical research ［J］.China Cancer Clinical,2008,35(6):306-309.［袁葆琳，张涛,罗建奇,等.三维适形放射治疗(3DCRT)非小细胞肺癌临床研究［J］． 中国肿瘤临床，2008,35(6):306-309．］
［4］Le Péchoux C.Role of postoperative radiotherapy in resected non-small cell lung cancer:A reassessment based on new data［J］.Oncologist,2011,16(5):672-681.
［5］Lagerwaard FJ，Verstegen NE，Haasbeek CJ，et al．Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non small cell lung cancer［J］． Int J Ｒadiat Oncol Biol Phys，2012，83(7):348-353．
［6］Liu Weishuai,Zhao Lujun,Liu Zhiyan,et al.Efficacy analysis of short course,large fractionated palliative radiotherapy for advanced non-small cell lung cancer ［J］.Chinese Cancer Clinic,2013,40(20):1240-1243.［刘维帅,赵路军,刘志艳,等.进展期非小细胞肺癌短疗程大分割姑息放疗疗效分析［J］.中国肿瘤临床,2013,40(20):1240-1243.］
［7］Eileen Zhang,Wang Wei.Conventional segmentation and large segmented three-dimensional conformal radiotherapy for non-small cell lung cancer combined with superior vena cava compression syndrome ［J］.Journal of Kunming Medical University,2016,37(6):77-81.［张爱玲,王维.常规分割与大分割三维适形放射治疗非小细胞肺癌合并上腔静脉压迫综合征［J］.昆明医科大学学报,2016,37(6):77-81.］
［8］Sun Yunan,Duan Qiongyu,Niu Nan,et al.Comparative efficacies and toxicity of stereotactic body radiotherapy with or without chemotherapy in patients with large (≥5 cm)non-small cell lung carcinoma［J］.Modern Oncology,2018,26(03):0360-0363.［孙宇楠，段琼玉，牛楠,等.立体定向体部放疗联合或不联合化疗治疗≥5 cm的非小细胞肺癌的临床疗效及不良反应［J］.现代肿瘤医学，2018，26（03）：0360-0363.］
［9］Graves EE,Maity A,Le QT.The tumor micro environment in non-small-cell lung cancer［J］.Semin Radiat Oncol,2010,20(3):156-163.
［10］Song YC,You JQ,Yuan ZY,et al.A preliminary probe into the movement of pancreatic lesions and factors that influence it［J］.Br J Radiol,2010,83(990):505-508.
［11］Zsófia Pénzváltó,Bálint Tegze,A Marcell Szász.Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45［J］.Cancer Cell Lines,2014,8(3):1-11.
［12］Gurtner K,Ebert N,Pfitzmann D,et al.Effect of combined irradiation and EGFR/ErbB inhibition with BIBW 2992 on proliferation and tumor cure in cell lines and xenografts［J］.Radiation Oncology,2014,9(1):261-268.
［13］Worthington J,Bertani M,Chan HL,et al.Transcriptional profiling of ErbB signalling in mammary luminal epithelial cells-interplay of ErbB and IGF1 signalling through IGFBP3 regulation［J］.BMC Cancer,2010,10:490-510.
［14］Sun Jian,Liu Ningbo,Qu Chenhui,et al.Identifying the genetic pattern of conventional fractionated and hypofractionated radiotherapy using whole genome expression microarray in a non-small-cell lung cancer cell line［J］.Chin J Clin Oncol,2013,40(21):1280-1283.［孙健，刘宁波，曲晨慧,等.全基因组表达谱芯片筛选非小细胞肺癌常规分割和大分割放疗差异基因的初步研究［J］.中国肿瘤临床,2013，40（21）：1280-1283.］
［15］Liu Ningbo,Wang Ping.Progress in the study of large fractionation radiotherapy sensitivity and PI3K/AKT/mTOR signaling pathway in non-small cell lung cancer［J］.Chinese Cancer Clinical,2013,40(19):1196-1198.［刘宁波，王平.非小细胞肺癌大分割放疗敏感性与PI3K/AKT/mTOR信号通路研究进展［J］.中国肿瘤临床,2013,40(19):1196-1198.］
［16］Chang JY，Senan S，Paul MA，et al.Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer：Apooled analysis of two randomized trials［J］.Lancet Oncol，2015，16（6）：630-637.

Memo

Memo:
2016年南通市科技计划项目（编号：YYZ16023)
Last Update: 1900-01-01